A. Industry structure and developments
The Companys business is divided in to single segment i.e Pharmaceutical Formulations. Given the strain on the economic scenario and slow down-market condition, company have not achieved well as compared to previous years figures. Your directors are trying their best to maximize the profit soft he Company and the stake holders as a whole.
B. Segment-wise or product-wise performance:
The Companys exports have decreased to Rs 7,490.77 lakh from the previous years Rs 9,474.85 lakh
C. Opportunities, Threats, Risk & Concerns:
The Company is in the process of looking for ward to enhance its exports in order to increase the valuation of the company as a whole. The competition to your company has continued to be significant factor which is to be taken care of while formulating the growth plan & strategies. Given its strong technological base, wide market range of products, we are equipped to meet the challenges.
D. Outlook:
Given the strain on the economic scenario, your directors are trying their best to maximize the profits of the Company and the stakeholders as a whole.
E. Internal control systems and their adequacy:
The Companys defined organizational structure, documented policy guidelines and adequate internal controls ensure efficiency of operations, compliance with internal policies, applicable laws and regulations, protection of resources and assets and accurate reporting of financial transactions. The Company continuously upgrades these systems in line with best available practices.
F. Discussion on financial performance with respect to operational performance:
As mentioned in Boards report and financial statement, the management highlighted the financial performance of the company.
G. Material developments in Human Resources / Industrial Relations front, including number of people employed:
Human resources continue to be one of the critical assets of the organization. Attracting relevant talent remains the Companys key focus. It pays special attention to training, welfare and safety of its people, strengthening human capabilities.
Ratios: As per Schedule III of the Companies Act, 2013 requirements
| Ratio | Current Period | Previous Period | % Variance | Reason for variance |
| Current Ratios (in times) | 6.48 | 7.07 | -8.39 | Due to decrease in trade receivables and Cash & Cash equivalents |
| Debt Equity Ratio (in times) | NA | NA | NA | NA |
| Debts Service Coverage Ratio (in times) | NA | NA | NA | NA |
| Return on Equity Ratio (in %) | 7.98 | 12.76 | (37.41) | Decrease in Net profit |
| Inventory Turnover Ratio (in times) | 5.55 | 9.04 | (38.63) | Decrease in revenue from sale of product has resulted in decrease in Inventory turnover ratio |
| Trade Receivable Turnover Ratio (in times) | 2.68 | 3.66 | (26.91) | Decrease in sales of Products has resulted in decrease of trade receivables |
| Trade Payable Turnover Ratio (in times) | 5.55 | 4.82 | 15.35 | Decrease in production has resulted in decrease in production |
| Net Capital Turnover Ratio (in times) | 0.57 | 0.82 | (30.44) | Due to decrease in revenue from sale of product |
| Net Profit Ratio (in %) | 19.07 | 21.00 | (9.21) | Decrease in revenue from operation has decreased the profit as compared to last year |
| Return on Capital Employed (in %) | 13.61 | 22.19 | (38.69) | Decrease in revenue from operation has resulted in decrease in return on capital employed as compared to last year |
| Return on Investments (in %) | 55.40 | 425.53 | (86.98) | Due to decrease in gain on sale of investment |
| By Order of the Board |
| For Coral Laboratories Limited |
| Sd/- |
| Girish M Dhameja |
| Whole Time Director |
| (DIN: 07798455) |
| Sd/- |
| Sushma Kadkade |
| Director & CFO |
| (DIN: 07791735) |
| Place: Mumbai |
| Date: August 14, 2026 |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
